. Author manuscript; available in PMC: 2014 Sep 19.

Published in final edited form as: Sci Transl Med. 2012 Feb 8;4(120):120ra15. doi: 10.1126/scitranslmed.3002865

Table 1.

Subject enrollment characteristics and injection details. Subjects are listed in the order that they were enrolled in the FO study. Eye #1, retina that was initially injected; Eye #2, retina that received the FO injection. All subjects were followed through FOd180. Visual acuity is expressed in LogMAR (log of the minimum angle of resolution). Higher values indicate poorer vision (see Supplementary Methods). Hand motion vision was assigned a conservative LogMAR of 2.6.

Patient ID	Age at readministration	Sex	Follow-up after initial injection (years)	AAV2-hRPE65v2 dose (vg)/volume (μl)		Visual acuity (pre/post)		RPE65 mutation
Patient ID	Age at readministration	Sex	Follow-up after initial injection (years)	Eye #1	Eye #2	Eye #1	Eye #2	RPE65 mutation
CH12	46	F	2.1	1.5 × 10¹¹/300 (high/high)	1.5 × 10¹¹/300 (high/high)	2.6/2.16	2.6/2.0	K303X/W431C
CH11	27	F	2.3	4.8 × 10¹⁰/150 (medium/low)	1.5 × 10¹¹/300 (high/high)	0.76/0.77	0.64/0.58	V473D/V473D
NP01	29	F	3.7	1.5 × 10¹⁰/150 (low/low)	1.5 × 10¹¹/300 (high/high)	1.5/1.6	1.83/1.6	E102K/E102K